The most prevalent treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) consist of pharmacological interventions (Yoo et al., 2016), behavioral therapy, or a combination of these (Camp et al., 2021). Among the pharmacological agents, stimulant medications are the most applied treatment, and their effectiveness in reducing symptom severity has been consistently and empirically demonstrated. (Gilboa & Helmer, 2020). Despite this, public health statistics highlight a striking treatment gap: in the United States, an estimated 6.1 million children are currently diagnosed with ADHD, yet approximately 23% receive no therapeutic intervention—pharmacological or behavioral (Camp et al., 2021). Another national study reported that among children between the ages of 4 and 17 formally diagnosed with ADHD, nearly 69% of the examined population receive some form of pharmacological treatment. The increasing popularity of pharmacological therapy is not limited to North America; similar patterns of prescription rate growth have been observed in Europe and Asia (Davidovitch et al., 2017).
While stimulant medications are frequently successful in attenuating core ADHD symptoms such as impulsivity, hyperactivity, and inattention, they are also associated with a substantial adverse effects. Documented side effects include insomnia, appetite suppression, headaches, nausea, and gastrointestinal discomfort. Furthermore, several stimulant agents have been shown to elevate blood pressure and accelerate heart rate, while psychiatric and behavioral side effects have also been noted. These may vary in intensity and manifestation, ranging from irritability and aggression to more severe psychological outcomes, including suicidal ideation (Camp et al., 2021). Additionally, pharmacological treatments are ineffective in approximately 30% of children diagnosed with ADHD (White et al., 2020). Beyond clinical inefficacy, Michel (2018) argues that reliance on pharmacological therapy may induce a detrimental psychological effect in children, fostering a perception of inability to independently cope with their disorder. Such an externalized attribution of control can erode self-confidence, diminish perceived self-efficacy, and ultimately undermine intrinsic motivation.
Given these findings, the use of stimulant medications, although widespread, remains controversial. A considerable body of research has addressed the potential long-term negative consequences of stimulant therapy, particularly the development of substance use disorders in adolescence or adulthood compared with their untreated peers. These concerns are rooted in the properties of stimulants such as methylphenidate, methamphetamine, amphetamine derivatives, and opioid-like compounds, which act on dopaminergic pathways. Because dopaminergic dysregulation plays a central role in the pathophysiology of addiction, parents fear that stimulant exposure in childhood may predispose their children to substance misuse.
Empirical evidence, however, remains nuanced. A meta-analysis synthesizing data from multiple longitudinal studies concluded that stimulant treatment does not increase the risk of substance dependence; in fact, some findings suggest a possible protective effect (Camp et al., 2021). Wilens (2004) reviewed six independent studies: one reported an increased risk, one found no significant differences, while four indicated a reduced likelihood of subsequent substance misuse. Wilens summarized that stimulant pharmacotherapy, rather than predisposing to addiction, potentially halves the risk of drug use. Despite this growing body of supportive evidence, negative public perception of stimulant medications, together with their side effects, continues to motivate parents and caregivers to seek non-pharmacological alternatives or complementary therapies for their children’s ADHD (Camp et al., 2021).
Reflecting this multidimensional reality, the American Academy of Pediatrics currently recommends a combined therapeutic approach, integrating pharmacological treatment with behavioral interventions. Cognitive-behavioral approaches have demonstrated efficacy in either reducing overall ADHD symptoms or in targeting specific dimensions of the disorder (Gilboa & Helmer, 2020). Such interventions include neurostimulation techniques (Camp et al., 2021), parent training programs, school-based behavioral interventions, and cognitive training (Yoo et al., 2016). In addition, neurofeedback has been increasingly studied as a promising non-invasive method to enhance self-regulation and attention (Camp et al., 2021; Sonuga-Barke et al., 2013). Physical exercise has also been identified as a supportive intervention, benefiting not only general physical health but also for executive functioning, attentional control, and emotional regulation in children with ADHD (Yoo et al., 2016).
In summary, while stimulant pharmacotherapy remains the most prevalent and empirically supported intervention for ADHD symptom management, substantial concerns about side effects, long-term psychological consequences, and parental apprehensions remain unresolved. Scientific literature underscores the importance of a multimodal approach that integrates pharmacological and behavioral interventions, maximizing therapeutic efficacy while minimizing risks. Future research should continue to examine the comparative effectiveness of these approaches, with particular attention to individual variability in treatment response, developmental trajectories, and long-term psychosocial outcomes, investigating these aspects in the both children and adults.
